NCT05476172

Brief Summary

This randomized controlled study aims to investigate the efficiency of medical treatment modalities in endometriosis patients. The study protocol involves two arms. (Dienogest Group and Noretindrone Acetate Group). The patients diagnosed with endometriosis are randomized depending on their protocol ids. The Dienogest group is prescribed 5 mg dienogest per day and neta group is prescribed 5 mg neta per day. The pain scores will be analyzed six months and twelve months after treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2021

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

July 7, 2022

Completed
20 days until next milestone

First Posted

Study publicly available on registry

July 27, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

July 21, 2023

Status Verified

July 1, 2023

Enrollment Period

2.2 years

First QC Date

July 7, 2022

Last Update Submit

July 20, 2023

Conditions

Keywords

endometriosisnorethindrone acetatedienogestchronic pelvic painprogesterone

Outcome Measures

Primary Outcomes (2)

  • Chronic Pelvic Pain

    Numeric Score before and after treatment

    Change from Baseline Score at 6 months

  • Chronic Pelvic Pain

    Numeric Score before and after treatment

    Change from Baseline Score at 12 months

Secondary Outcomes (2)

  • Side Effect Rate

    Rate of Side Effect from baseline at 6 months

  • Side Effect Rate

    Rate of Side Effect from baseline at 12 months

Study Arms (2)

Dienogest

ACTIVE COMPARATOR

Patients with endometriosis are prescribed dienogest for treatment.

Drug: Dienogest Pill

Norethindrone Acetate

ACTIVE COMPARATOR

Patients with endometriosis are prescribed Norethindrone Acetate for treatment.

Drug: Norethindrone Acetate

Interventions

The effect of dienogest on endometriosis pain symptoms.

Also known as: Visanne Group
Dienogest

The effect of Norethindrone Acetateon endometriosis pain symptoms.

Also known as: Primolut-N Group
Norethindrone Acetate

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • years aged women diagnosed with endometriosis

You may not qualify if:

  • malignancy
  • need for surgery
  • pregnancy desire

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Uludag University

Bursa, Nilufer, Turkey (Türkiye)

Location

Related Publications (1)

  • Gurbuz TB, Aslan K, Kasapoglu I, Muzii L, Uncu G. Norethindrone acetate versus dienogest for pain relief in endometriosis related pain: A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:113940. doi: 10.1016/j.ejogrb.2025.113940. Epub 2025 Mar 29.

MeSH Terms

Conditions

Endometriosis

Interventions

dienogestNorethindrone Acetate

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

NorethindroneNorpregnenesNorpregnanesNorsteroidsSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Kiper Aslan, Assoc. Prof.

    Uludag University

    PRINCIPAL INVESTIGATOR
  • Isil Kasapoglu, Assoc. Prof.

    Uludag University

    PRINCIPAL INVESTIGATOR
  • Gurkan Uncu, Prof.

    Uludag University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 7, 2022

First Posted

July 27, 2022

Study Start

April 1, 2021

Primary Completion

May 30, 2023

Study Completion

June 30, 2023

Last Updated

July 21, 2023

Record last verified: 2023-07

Locations